9th Congress of the European Academy of Neurology

Brain disorders – comprising mental illness, neurologic conditions, and stroke – account for over 15 percent of global health loss (how much healthy life is lost due to early death, illness, or ability) in the Global Burden of Disease (GBD) study presented at EAN 2023.

Retinal thinning predicts disability in patients newly diagnosed with relapsing multiple sclerosis (MS), an immune-mediated disease affecting the brain and spinal cord, in a new study presented at EAN 2023.

Photobiomodulation helps to reduce the severity of chemotherapy-induced peripheral neuropathy (CIPN) and increases mobility in cancer patients as shown in a study presented at EAN 2023.

Experimental gene therapy appears to improve eyesight in patients with a severe progressive form of Leber’s hereditary optic neuropathy (LHON) in an early access programme.